Impact of everolimus starting dose on antiproliferative efficacy in patients with neuroendocrine tumors – Experiences from a tertiary referral center

#3672

Introduction: Everolimus is approved at a full dose of 10 mg daily for the treatment of advanced neuroendocrine tumors (NETs) but associated with relevant toxicities. Hence dose reductions are a frequent event in clinical practice.

Aim(s): The objective was to evaluate the impact of dosing on progression-free survival (PFS).

Materials and methods: This retrospective analysis assessed patients with advanced NET treated with everolimus at the Medical University Vienna between 2010 and 2021.

Conference:

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Melhorn P, Macheiner S, Wolff L, Kretschmer-Chott E,

Keywords: everolimus, dose reduction, advanced NET, systemic therapy, medical oncology,